Growth Metrics

Lemaitre Vascular (LMAT) Liabilities and Shareholders Equity (2016 - 2025)

Lemaitre Vascular (LMAT) has disclosed Liabilities and Shareholders Equity for 16 consecutive years, with $615.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Liabilities and Shareholders Equity rose 11.58% to $615.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.3 billion, a 42.62% increase, with the full-year FY2025 number at $615.7 million, up 11.58% from a year prior.
  • Liabilities and Shareholders Equity was $615.7 million for Q4 2025 at Lemaitre Vascular, up from $598.1 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $615.7 million in Q4 2025 to a low of $246.5 million in Q2 2021.
  • A 5-year average of $379.8 million and a median of $330.2 million in 2023 define the central range for Liabilities and Shareholders Equity.
  • Peak YoY movement for Liabilities and Shareholders Equity: decreased 3.6% in 2021, then skyrocketed 59.13% in 2024.
  • Lemaitre Vascular's Liabilities and Shareholders Equity stood at $292.8 million in 2021, then rose by 6.04% to $310.5 million in 2022, then rose by 11.69% to $346.8 million in 2023, then surged by 59.13% to $551.8 million in 2024, then increased by 11.58% to $615.7 million in 2025.
  • Per Business Quant, the three most recent readings for LMAT's Liabilities and Shareholders Equity are $615.7 million (Q4 2025), $598.1 million (Q3 2025), and $577.6 million (Q2 2025).